1、simon-Christian SchulerLukas HirnSeven secret ingredients for successfully launching and commercializing a biopharmas first drug in EuropeUnderstanding what drives a products valueand how to fully extract it ContentsThe idea in short:Shifting gears to succeed 3Introduction:Searching for the right op

2、portunities ahead 4Characteristics of first drug launches in Europe:Identifying common patterns 6Opportunities and reasons to commercialize:Striving for increased shareholder value 9The seven secret ingredients for success:Pursuing the full extraction of a drugs economic value 12Conclusion:The dos a

3、nd donts Hunting for advice 25Authors 293The idea in short:Shifting gears to succeedTransitioning from an R&D-focused biopharma company to a commercially viable operation is already a challenging endeavor,and the prospect of having to master complex European launch requirements while also steering U

4、S business makes this shift even more daunting.To help companies assess the general viability of such ventures,this Simon-Kucher whitepaper identifies common characteristics among independent operations and carves out key managerial implications to enable business leaders to properly analyze,prepare

5、 for,and execute a successful launch for their companys first drug in Europe and also establish a fully integrated(bio-)pharmaceutical company(FIPCO).Extensive quantitative and qualitative research,covering more than 20 company analog cases,approximately 4,500 data points,and 18 industry expert disc

6、ussions,shows that unlocking significant price potential for the target asset is one of the key prerequisites to make this organizational leap.The primary factors driving a drugs price potential are a high level of unmet medical need,high disease severity,orphan drug status/relative rarity of the di